CSL shares: 1 number that investors shouldn't ignore

This one number has me rethinking a CSL investment…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Well, one of the biggest pieces of news on the ASX so far this week has been the blockbuster earnings of healthcare giant CSL Ltd (ASX: CSL). CSL delivered its full-year results for FY2026 yesterday. And boy, did the markets grab them (and plenty of CSL shares) and run.

By the end of yesterday's session, the CSL share price had rocketed a massive 17.25% for its best day in 20 years.

As we covered yesterday, there were a lot of lukewarm numbers in this ASX 200 healthcare stock's latest report. The company reported total revenues of US$15.89 billion for the year ended 30 June 2026. That was down 1% year-on-year. Underlying net profits after tax dropped 2% to US$3.1 billion.

A number of one-off costs and impairments drove CSL to a statutory net loss after tax of US$2.6 billion.

However, as my Fool colleague Mark discussed yesterday, it seems that the unbridled optimism we have seen for CSL shares this week has stemmed from its optimistic guidance for FY2027 and beyond.

CSL told investors to expect underlying net profits after tax growth of around 5% over FY27. This indicates a return to form is on the cards for a company that repeatedly dazzled investors for the decade leading up to 2020, before a series of events tanked the company's fortunes.

Hopefully, CSL can deliver this turnaround. But now, I want to focus on one metric that has caught my eye in CSL's latest numbers.

CSL shares surge despite a dividend hold

That metric is the final dividend that CSL will pay out in October. Yesterday, CSL revealed that this dividend will be worth US$1.60 per share. Coupled with April's interim dividend of US$1.30 per share, the company is set to dole out a total of US$2.92 in dividends per share in 2026.

That metric is significant because it marks only the second time that CSL will not be delivering a dividend hike to its shareholders. In fact, the last time that CSL didn't increase its year-on-year payouts was in 2022, largely thanks to the aftermath of the pandemic. You'd have to go back at least another decade to find any more instances of a dividend hold from this company.

This is a personal disappointment for me. I bought CSL shares many years ago, in part thanks to its strong history of dividend growth. As such, I was rather dismayed to see another hold on CSL's 2026 payout. A company's dividend growth is, in my view, one of the most vital indicators of a company's health. It is difficult to fudge and provides a sharp insight into the health of a company. Not to mention the fact that ASX shares that consistently grow their dividends over time tend to be market beaters.

Now, CSL has been upfront about its challenges for a while now. So this hold isn't really a surprise. But it is still something I didn't want to see. That's why I'll be watching the payouts that this company declares next year like a hawk.

Motley Fool contributor Sebastian Bowen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman's hair is blown back and her face is in shock at this big news.
Healthcare Shares

CSL shares rebound 79% from multi-year low: Here's what brokers tip next

The ASX biotech company announced its FY26 results yesterday.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Buy $5,000 of Cochlear shares today and it could be worth this much in 12 months

Find out what brokers tip for this ASX healthcare stock next.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Earnings Results

Healius posts FY26 revenue growth, narrows underlying loss

Its underlying loss narrowed, but its reported loss after tax widened to $415.6 million.

Read more »

patient with doctor, medical company, medical insurance
Healthcare Shares

CSL shares just had their best day in 20 years. What did I just miss?

A US$2.6 billion loss sent CSL shares soaring. Here is why.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

EBOS FY26 earnings: profit edges higher, dividend steady

EBOS Group posts a rise in FY26 profit and revenue as it maintains its final dividend for shareholders.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Bell Potter tips more than 140% upside for this out of favour ASX biotech

This company has made good progress over the past quarter.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Why are Pro Medicus shares surging more than 10%?

The shares are still short of one broker's price target.

Read more »

Health professional looking at a laptop.
Earnings Results

Cogstate posts record FY26 earnings, boosts dividend

Cogstate delivers record FY26 earnings growth and increases its dividend as it invests in AI-driven expansion.

Read more »